Clinical Trial Search

Primary: Proportion of Participants With Improved Sensitivity for Detection of Early-stage Gastric Cancer in CDH1 Germline Mutation Carriers Compared to the Cambridge Method — 1…

Primary: Incidence of Treatment-Emergent Adverse Events — 9; 2; 6; 2 participants

Primary: Least Square Mean Change in Baseline to Week 8 on Z-score in Combined Digit Symbol Substitution Test (DSST) — 0.332; 0.184 score on a scale

Primary: Percentage of Patients That Respond to Treatment — 18 Participants

Primary: Percentage of Participants With Treatment Emergent Adverse Events (TEAEs) — 66.7; 41.7; 16.7; 0 Percentage of participants

Primary: Efficacy of ADX-102 on Ocular Discomfort Using the Ora Calibra® Ocular Discomfort Scale. — -0.81; -0.75; -0.82 units on a scale

Primary: Number of Participants With Adverse Events (AEs) — 18; 15 Participants

Primary: Dose Escalation Phase: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 3; 3; 3; 3 Participants

Primary: Number of Participants With Pre-specified Treatment-related Adverse Events — 3; 5; 3 participants

Primary: Outcome 1: Serial HIV-1 RNA Levels in Breastmilk. — 2.74; 2.03; 1.70; 1.70 Log10 Viral load copies/ml

Primary: Conjunctival Redness Assessed Via Digital Photography Over 90 Minutes in the Dry Eye Chamber — 0.33; 0.44 score on a scale

Primary: Progression-free Survival (PFS) — 10.3; 8.3 months

Primary: Overall Response Rate in Each Arm — 1; 1; 2; 1 Participants

Primary: Number of Participants Reporting Serious Adverse Events (SAEs) and Non-SAEs — 11; 12; 14; 14 Participants

Primary: Percentage of Participants With Local and Systemic Solicited AEs by Severity During the First 7 Days After Each Vaccination. — 78.2; 80.0; 88.0; 77.4 percent of…